Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
meclizine histamine h1 receptor small molecule NA drugbank , DGIDB Disease Management[MeSHID:D019468]
Vertigo[MeSHID:D014717]
Labyrinthine disorder[MeSHID:D007759]
Meniere Disease[MeSHID:D008575]
Nausea[MeSHID:D009325]
Vomiting[MeSHID:D014839]
Radiation Sickness[MeSHID:D011832]
Dizziness[MeSHID:D004244]
Motion Sickness[MeSHID:D009041]
Vestibular Labyrinth[MeSHID:D014722]
Labyrinthitis[MeSHID:D007762]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.41 approved antagonist
meclizine orphan nuclear receptor nr1i3 NA Successful target TTD , DGIDB Disease Management[MeSHID:D019468]
Vertigo[MeSHID:D014717]
Labyrinthine disorder[MeSHID:D007759]
Meniere Disease[MeSHID:D008575]
Nausea[MeSHID:D009325]
Vomiting[MeSHID:D014839]
Radiation Sickness[MeSHID:D011832]
Dizziness[MeSHID:D004244]
Motion Sickness[MeSHID:D009041]
Vestibular Labyrinth[MeSHID:D014722]
Labyrinthitis[MeSHID:D007762]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 2.27 approved antagonist
meclizine nuclear receptor subfamily 1 group i member 3 small molecule NA drugbank , DGIDB Disease Management[MeSHID:D019468]
Vertigo[MeSHID:D014717]
Labyrinthine disorder[MeSHID:D007759]
Meniere Disease[MeSHID:D008575]
Nausea[MeSHID:D009325]
Vomiting[MeSHID:D014839]
Radiation Sickness[MeSHID:D011832]
Dizziness[MeSHID:D004244]
Motion Sickness[MeSHID:D009041]
Vestibular Labyrinth[MeSHID:D014722]
Labyrinthitis[MeSHID:D007762]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 2.27 approved inverse agonist,antagonist
meclizine nuclear receptor subfamily 1 group i member 3 small molecule NA drugbank , DGIDB Disease Management[MeSHID:D019468]
Vertigo[MeSHID:D014717]
Labyrinthine disorder[MeSHID:D007759]
Meniere Disease[MeSHID:D008575]
Nausea[MeSHID:D009325]
Vomiting[MeSHID:D014839]
Radiation Sickness[MeSHID:D011832]
Dizziness[MeSHID:D004244]
Motion Sickness[MeSHID:D009041]
Vestibular Labyrinth[MeSHID:D014722]
Labyrinthitis[MeSHID:D007762]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 2.27 approved inverse agonist
meclizine orphan nuclear receptor nr1i3 NA Successful target TTD , DGIDB Disease Management[MeSHID:D019468]
Vertigo[MeSHID:D014717]
Labyrinthine disorder[MeSHID:D007759]
Meniere Disease[MeSHID:D008575]
Nausea[MeSHID:D009325]
Vomiting[MeSHID:D014839]
Radiation Sickness[MeSHID:D011832]
Dizziness[MeSHID:D004244]
Motion Sickness[MeSHID:D009041]
Vestibular Labyrinth[MeSHID:D014722]
Labyrinthitis[MeSHID:D007762]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 2.27 approved unknown
click here to return to the previous page